We found previously that short-term curcumin gavage stimulated mouse hepatic fibroblast growth factor 21 (Fgf21) expression. Here we conducted mechanistic exploration and investigated the potential pathophysiological relevance on this regulation. Fgf21 stimulation was observed at messenger RNA and protein levels in mice with daily curcumin gavage for 4 or 8 days and in primary hepatocytes with curcumin treatment. Using peroxisome proliferator-activated receptor a (PPARa) agonist and antagonist, along with luciferase reporter and chromatin immune-precipitation approaches, we determined that curcumin stimulates Fgf21 transcription in a mechanism involving PPARa activation. High-fat diet (HFD) feeding also increased mouse hepatic and serum Fgf21 levels, whereas dietary curcumin intervention attenuated these increases. We found that HFD feeding reduced hepatic expression levels of genes that encode FGFR1 and bKlotho, PGC1a, and the targets of the PPARa-PGC1a axis, whereas concomitant curcumin intervention restored or partially restored their expression levels. Importantly, hepatocytes from HFD-fed mice showed a loss of response to FGF21 treatment on Erk phosphorylation and the expression of Egr1 and cFos; this response was restored in hepatocytes from HFD-fed mice with curcumin intervention. This investigation expanded our mechanistic understanding of the metabolic beneficial effects of dietary curcumin intervention involving the regulation of Fgf21 production and the attenuation of HFD-induced Fgf21 resistance. (Endocrinology 158: 277-292, 2017) 
We found previously that short-term curcumin gavage stimulated mouse hepatic fibroblast growth factor 21 (Fgf21) expression. Here we conducted mechanistic exploration and investigated the potential pathophysiological relevance on this regulation. Fgf21 stimulation was observed at messenger RNA and protein levels in mice with daily curcumin gavage for 4 or 8 days and in primary hepatocytes with curcumin treatment. Using peroxisome proliferator-activated receptor a (PPARa) agonist and antagonist, along with luciferase reporter and chromatin immune-precipitation approaches, we determined that curcumin stimulates Fgf21 transcription in a mechanism involving PPARa activation. High-fat diet (HFD) feeding also increased mouse hepatic and serum Fgf21 levels, whereas dietary curcumin intervention attenuated these increases. We found that HFD feeding reduced hepatic expression levels of genes that encode FGFR1 and bKlotho, PGC1a, and the targets of the PPARa-PGC1a axis, whereas concomitant curcumin intervention restored or partially restored their expression levels. Importantly, hepatocytes from HFD-fed mice showed a loss of response to FGF21 treatment on Erk phosphorylation and the expression of Egr1 and cFos; this response was restored in hepatocytes from HFD-fed mice with curcumin intervention. This investigation expanded our mechanistic understanding of the metabolic beneficial effects of dietary curcumin intervention involving the regulation of Fgf21 production and the attenuation of HFD-induced Fgf21 resistance. (Endocrinology 158: 277-292, 2017) F ibroblast growth factor 21 (Fgf21) is mainly produced in and released by the liver in response to fasting (1) (2) (3) (4) . The lack of the conventional heparin binding domain of this unique FGF family member allows this hepatokine to diffuse away from its site of origin and function as a hormone (4) (5) (6) . Intensive investigations have revealed that the elevation of Fgf21 production during fasting occurs via a mechanism involving activation of peroxisome proliferator-activated receptor a (PPARa) (1, 2, 7, 8) . During the adaptive starvation response, Fgf21 may induce hepatic expression or activation of peroxisome proliferator-activated receptor g coactivator 1-a (PGC1a), which facilitates fatty acid oxidation, tricarboxylic acid cycle flux, and gluconeogenesis (9) .
Over the past a few years, we have seen growing evidence for the therapeutic potential of Fgf21 in metabolic disorders, including diabetes and its complications, obesity, dyslipidemia, and liver steatosis, in humans and in animal models (4, (10) (11) (12) (13) (14) (15) ; however, animals or human subjects with obesity or diabetes were paradoxically found to have elevated plasma Fgf21 levels, raising the hypothesis that obesity is an Fgf21-resistant state (16) (17) (18) (19) (20) (21) . Indeed, Fisher et al. (16) have shown that highfat/high-sucrose diet-induced obese mice displayed an attenuated response to Fgf21 treatment, associated with reduced messenger RNA (mRNA) expression of FGF receptors in the liver and white adipose tissue. In a mouse model with mild nonalcoholic fatty liver disease, Rusli et al. (22) demonstrated that an elevated plasma Fgf21 level was associated with decreased expression of the gene that encodes the Fgf21 co-receptor bKlotho.
Curcumin, anthocyanin, and resveratrol are the most studied dietary plant polyphenols (23, 24) . As a traditional medicine and the major component of turmeric, curcumin possesses antimicrobial, insecticidal, cardioprotective, radioprotective, and anticancer properties (24) . Importantly, several preclinical investigations have shown the effect of curcumin in improving insulin signaling and reducing body weight gain in high-fat diet (HFD)-fed mice (25) (26) (27) and have attributed such effects to the anti-inflammation and antioxidative stress functions (25, 26, 28, 29) . A recent small-scale clinical trial indicated that curcumin intervention in prediabetic subjects lowered the number of individuals who eventually developed type 2 diabetes (T2D) (30) . Thus, the nutraceutical curcumin possesses great potential in the prevention and treatment of obesity, diabetes, and other metabolic disorders in which insulin resistance plays a fundamental role.
We demonstrated very recently that daily curcumin gavage for 6 days improved insulin signaling in mice that received dexamethasone injections (31) . In that study, we also noticed the stimulation of hepatic Fgf21 protein expression by curcumin gavage (31) . Here we conducted a mechanistic exploration examining Fgf21 induction by curcumin treatment in vivo and in vitro and investigated the potential pathophysiological relevance of the role of curcumin on Fgf21 production and function in the HFD-fed mouse model. Our findings suggest the existence of both a shortterm stimulatory effect of curcumin on Fgf21 production and a long-term effect of dietary curcumin intervention on attenuating Fgf21 resistance in mice consuming a HFD.
Materials and Methods

Reagents
Curcumin was purchased either from Sigma-Aldrich (St. Louis, MO) for in vitro cell culture experiments or from Organika Health Products (Richmond, BC, Canada; a 95% standardized curcumin extract) for short-term gavage or longterm dietary intervention in mice. The PPARa antagonist GW6471 (G5045) and the agonist Wy14643 (C7081) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Actinomycin D was purchased from Calbiochem (La Jolla, CA). Human recombinant Fgf21 was from Novoprotein Scientific Inc. (Summit, NJ). The cyclic adenosine monophosphatepromoting agents forskolin and 3-isobutyl-1-methylxanthine (IBMX) were from Sigma-Aldrich.
Animals and animal experimental design
Eight-week-old, male C57BL/6J mice purchased from Charles River Laboratories (St. Laurent, QC, Canada) were housed at constant temperature (22°C) under a 12-hour light/ dark cycle with free access to food and water. The animal experiments and protocols were approved by the University Health Network Animal Care Committee and performed in accordance with the guidelines of the Canadian Council of Animal Care.
Experiment 1
The protocol for 6 days curcumin gavage was previously presented (31) . Briefly, male mice received either sesame oil (solvent) or curcumin (500 mg/kg body weight/d) gavage every day for 5 consecutive days. After 1 day of rest, an intraperitoneal insulin tolerance test was performed at day 7. A booster curcumin (or solvent) gavage was given on day 8. The mice were killed for liver tissue and serum collection on day 10. This experiment is defined as 6-day curcumin gavage.
Experiment 2
The same experiment as experiment 1 was performed, except the dosage of curcumin was reduced to 100 mg/kg body weight/ d for 4 or 8 days before animals were killed for liver tissue and serum collection.
Experiment 3
Eight-week-old male mice were fed a low-fat diet (LFD) or an HFD (60% Kcal from soybean fat) with or without curcumin (4 g/kg diet) for 12 weeks (26) . An intraperitoneal glucose tolerance test (IPGTT) was performed as previously described (26) .
Cell culture
The human HepG2 and mouse Hepa1-6 cell lines were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (32) . C57BL/6J male mice (8-12 weeks old) were used for primary hepatocyte isolation as described previously (33, 34) . Human hepatocytes were isolated from a 16-year-old male donor without a known hepatic disease, with the 2-step collagenase isolation method in the laboratory approved with Good Laboratory Practice. The study was approved by the Research Ethics Board of the University Health Network.
Fgf21, triglyceride, and free fatty acid measurements
The quantitative measurement of Fgf21 in mouse serum was performed with the Fgf21 Immunoassay Kit (catalogue number 32180) provided by Antibody and Immunoassay Services (The University of Hong Kong). Liver triglyceride contents were determined using the Serum Triglyceride Determination Kit (TR0100; Sigma-Aldrich). Details are provided in the Supplemental Methods.
Preparation of cell lysates and Western blotting
Whole-cell lysates from mouse liver tissue, primary hepatocytes, or cultured cell lines were prepared and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by Western blotting as previously described (35) . Antibodies for Western blotting are listed in Table 1 .
RNA extraction, real-time reverse transcription polymerase chain reaction, and the assessment of the effect of curcumin treatment on Fgf21mRNA stability TRI reagent (Sigma-Aldrich) was used for RNA extraction. Real-time polymerase chain reaction (PCR) was performed as previously described (36) . PCR primers are listed in Supplemental Table 1 . The method for assessing the effect of curcumin on Fgf21 mRNA stability is detailed in Supplemental Methods.
Luciferase assay, chromatin immunoprecipitation, and GAL4 nuclear receptor assay
The construction of the fusion gene constructs in which the expression of the luciferase (LUC) reporter is driven by an~1.5-kb or~3.1-kb mouse Fgf21 5 0 flanking sequence is detailed in the Supplemental Methods. The LUC assay was conducted as previously described (33) . The procedures for chromatin immunoprecipitation (ChIP) and quantitative ChIP (qChIP), as well as GAL4 nuclear receptor assay, are detailed in the Supplemental Methods. Supplemental Table 1 also contains the primers used in ChIP and qChIP.
Statistics
Quantitative results are expressed as a mean 6 standard deviation. For the comparison of 2 groups, the 2-tailed, unpaired Student t test was used in the statistical analysis, with significance at P , 0.05. Comparisons between groups with 1 treatment were determined by one-way analysis of variance with a post hoc Bonferroni test.
Results
Curcumin treatment increases hepatic Fgf21 expression
We found previously that 6-day curcumin gavage in dexamethasone-injected mice improved insulin signaling and increased hepatic Fgf21 protein levels (31) . Because dexamethasone can stimulate Fgf21 expression as well (37), we tested whether short-term curcumin gavage in mice on chow diet increases Fgf21 expression at both mRNA and protein levels in the absence of dexamethasone injection. As shown in Fig. 1 (A), 6-day curcumin . Plasma Fgf21 levels in mice in this set of experiments showed a trend toward an increased response to curcumin gavage, but the difference did not reach statistical significance [ Fig. 1(C) ]. To confirm the in vivo stimulatory effect, we repeated the curcumin gavage experiment in C57BL/6 mice and reduced the dosage from 500 to 100 mg/kg body weight/d. Figure 1 (D) and 1(E) shows that curcumin gavage for either 4 or 8 days increased hepatic Fgf21 and PPARa mRNA levels. We also observed an increase of Fgf21 expression at the protein level [ Fig. 1(F) and 1(G)]. In this experiment, the effect on random plasma Fgf21 level elevation was observed for mice receiving either 4-or 8-day curcumin gavage (Fig. 1H) . We then conducted in vitro experiments. As shown in Fig. 1 (I) and 1(J) and in Supplemental Fig. 1A , Fgf21 mRNA and protein expression in mouse primary hepatocytes can be stimulated by 12 hours of curcumin treatment at dosages varying from 0.5 to 10 mM but not at 20 mM, although the activation on Fgf21 protein expression at 0.5 mM was not always observable. Because curcumin was shown to exert antiinflammation and antioxidative stress effects in hepatocytes and elsewhere (25, 26) , we also tested its effect on reducing nuclear factor kB and increasing heme oxygenase-1 expression in mouse hepatocytes (Supplemental Fig. 3 ). Because these effects were achieved only at concentrations higher than 2 mM, we suggest that curcumin-stimulated Fgf21 expression is likely independent of its anti-inflammation and antioxidative stress effects.
PPARa is among mediators that convey the stimulatory effect of curcumin on Fgf21 transcription
PPARa positively regulates Fgf21 transcription, and 2 evolutionarily conserved PPAR response elements (PPREs) were located on the Fgf21 gene promoter regions (1, 8) . We have hence constructed the Fgf21-LUC reporter gene constructs in which the expression of the LUC reporter is driven by either~1.5 kb or~3.1 kb mouse Fgf21 gene 5 0 flanking region [ Fig. 2(A) ]. Figure 2 (B) and 2(C) shows that when either the 1.5 kb or the 3.1 kb Fgf21-LUC reporter plasmid was transiently transfected into HepG2 cells, 4 hours of curcumin treatment increased the LUC activity. The stimulatory effect of the cyclic adenosine monophosphate/protein kinase A activation agents [forskolin and IBMX (F/I)] on Fgf21-LUC reporter expression was also shown in Fig. 3 (B) and 3 (C), and Supplemental Fig. 4 shows that in the baby hamster kidney fibroblast naive cell system, curcumin, or F/I also stimulated the activity of the 1.5 kb Fgf21-LUC.
To determine the involvement of PPARa on curcuminstimulated Fgf21 expression, PPARa antagonist GW6471 and agonist Wy14643 were used. Figure 2 (D) and 2(E) shows that although GW6471 did not inhibit Fgf21 expression on its own, it blocked the stimulatory effect of curcumin treatment. Figure 2(F) and 2(G) shows that both curcumin and Wy14643 increased Fgf21 expression, and there was no appreciable synergistic effect when both curcumin and Wy14643 were used. We were unable to detect appreciable stimulation on PPARa expression at the protein level by curcumin treatment [ Fig. 2(E) and 2(G) ]. However, curcumin treatment (at both 1.5 and 2 mM) reduced PPARa (S12) phosphorylation, which has been suggested to be inversely associated with its activity (38) [ Fig. 2(H) ]. Figure 2 (I) shows that curcumin treatment generated no appreciable effect on attenuating the degradation of Fgf21 mRNA in the presence of actinomycin D. These observations collectively suggest that curcumin stimulates Fgf21 transcription via a mechanism involving PPARa activation.
Four-hour curcumin treatment increases the binding of PPARa to the Fgf21 gene promoter
ChIP was then used to test whether curcumin treatment increases binding of PPARa to Fgf21 promoter. Figure 3(A) shows the overall organization of mouse Fgf21 intron-exon organization and the 5 0 flanking region, including the locations of two PPREs. Figure 3 (B) and 3(C) shows that the anti-PPARa antibody, but not the control rabbit IgG, pulled down DNAs that contain PPRE1 and PPRE2. We were also able to pull down PPRE1 and PPRE2 with the RNA polymerase II antibody [ Fig. 3(B) and 3(C) ]. None of the 3 antibodies pulled down the intron II fragment that contains no PPRE [ Fig. 3  (D) ]. press.endocrine.org/journal/endoHFD feeding increases hepatic Fgf21, whereas curcumin intervention attenuates the increase Beneficial metabolic effects of curcumin intervention in mice were reported previously (25, 26) . We repeated the mouse study with 12 weeks of dietary curcumin intervention. Figure 4(A-C) shows the attenuation of curcumin intervention on HFD-induced body weight increase. Figure 4 (D) and 4(F) shows that there was no appreciable difference in food intake among the three groups of mice during the experimental period. Figure 4 (G) and 4(H) shows our IPGTT results, indicating that curcumin intervention attenuated the impairment on glucose disposal induced by HFD consumption.
The increases in serum and hepatic triglyceride and serum free fatty acid content with HFD feeding were attenuated with curcumin intervention [ Fig. 5(A-C) ]. In contrast to what we observed with short-term curcumin gavage, long-term curcumin intervention attenuated the increase of serum Fgf21 level induced by HFD feeding [ Fig. 5(D) ]. Therefore, we examined hepatic Fgf21 levels in these mice. As shown in Fig. 5 (E) and 5(F), HFD feeding increased hepatic Fgf21 protein levels, and this increase was completely blocked with curcumin intervention. Figure 5 (G) shows the stimulation of HFD feeding on hepatic Fgf21 mRNA expression, and this stimulation was also blocked with dietary curcumin intervention. Figure 5(H) shows that, when compared with LFD, 12 weeks of HFD feeding reduced the PPARa mRNA level, whereas curcumin intervention partially restored the PPARa mRNA level.
Curcumin intervention restores or partially restores the expression of genes that are altered by HFD feeding
Elevated plasma Fgf21 levels in obese mice were shown to be associated with reduced Fgfr1 or bKlotho expression (16, 22) . In our HFD-fed mouse model, hepatic Fgfr1 and bKlotho levels were also reduced, whereas curcumin intervention partially restored their expression levels [ Fig. 6(A) and 6(B) ]. Figure 6 (C) shows that HFD feeding also reduced hepatic levels of PGC1a, a key mediator of Fgf21 hepatic function (9) , and this reduction was completely blocked by curcumin intervention.
Acox1, Pdk4, and Ehhadh are suggested downstream targets of the PPARa/Fgf21/PGC1a axis, importantly involved in lipid b-oxidation (7). The hepatic expression levels of these three genes were reduced in HFD-fed mice, whereas 12-week dietary curcumin intervention restored the levels of Acox1 and Ehhadh but not Pdk4 [ Fig. 6(D) ].
Pnpla2, Lipe, and Mgll encode adipose triglyceride lipase, hormone-sensitive lipase, and monoacylglycerol lipase. Figure 6 (E-G) shows the repressive effect of HFD on their expression. Curcumin intervention at least partially restored their expression levels. The stimulation on hepatic PGC1a/Ppargc1a, Acox1, Pdk4, and Ehhadh expression was also observed in LFD-fed mice with 6-day curcumin gavage [Fig. 6(H) and 6(I) ].
Curcumin intervention likely attenuates Fgf21 resistance
The fact that long-term curcumin intervention attenuates hepatic Fgf21 production in HFD-fed mice prompted us to wonder whether curcumin attenuates Fgf21 resistance. To prove that Fgf21 resistance can be assessed in vitro, we treated mouse hepatocytes with 50 nM FGF21 overnight. Figure 7(A) shows that the treatment reduced Fgfr1 and bKlotho levels. Overnight high-dose Fgf21 treatment also attenuated the response of cells to further insulin treatment on Akt phosphorylation (Supplemental Fig. 6 ).
We then tested the in vitro effect of FGF21 in mouse hepatocytes on Erk phosphorylation. Supplemental Fig. 7 and Fig. 7(B) show that cells treated with 1, 2, or 10 nM FGF21 for 60 minutes (but not for 5 or 30 minutes) exhibited elevated Erk phosphorylation. Figure 7 (C) and 7(D) show that the activation was absent in hepatocytes isolated from HFD-fed mice and was restored in hepatocytes isolated from HFD-fed mice with curcumin intervention. Figure 7 (E-J) shows that the stimulatory effect of 1 and 10 nM FGF21 on the expression of Egr1 and cFos was absent in hepatocytes isolated from HFDfed mice and restored in hepatocytes isolated from HFDfed mice with curcumin intervention.
Discussion
After the recognition of Fgf21 as a novel hepatic hormone with potential in the treatment of T2D, obesity, liver steatosis, and other metabolic disorders (4, 10, 13, 14, 39, 40) , great efforts have been made to explore the mechanisms underlying its production under physiological and pathophysiological conditions (16, (41) (42) (43) (44) . Despite its therapeutic potential, elevated plasma Fgf21 levels were reproducibly demonstrated in subjects with T2D, coronary heart disease, and nonalcoholic fatty liver disease (20, (45) (46) (47) (48) (49) and in various animal models of diabetes or obesity (16, 20, 50, 51 ). In the current study, we have demonstrated the acute stimulatory effect of the dietary polyphenol compound curcumin on hepatic Fgf21 production in mice on chow diet or in hepatocytes in vitro, and our mechanistic exploration suggests that the stimulation of Fgf21 production involves the activation of the nuclear receptor PPARa, a key stimulator for hepatic Fgf21 gene transcription (1, 2, 8 ). More importantly, we press.endocrine.org/journal/endohave reproduced the observation that in the HFDinduced obese mouse model, hepatic Fgf21 mRNA and protein expression, as well as circulating Fgf21 level, were elevated. Our findings also revealed that long-term curcumin intervention attenuated the effect of HFD feeding, likely through the restoration of Fgf21 sensitivity.
The findings of our current study were initiated from a serendipitous observation. To determine whether curcumin administration could sensitize insulin signaling via a mechanism that is independent of its antiinflammation and antioxidative stress properties, we tested the effect of short-term curcumin gavage in an intraperitoneal dexamethasone-injection-induced insulinresistant mouse model (52) . We found that in this model, short-term (i.e., 6-day) curcumin gavage improved insulin signaling, and this improvement was associated with increased hepatic Fgf21 protein expression (31) . Because dexamethasone was shown to induce hepatic Fgf21 expression as well by the activation of the glucocorticoid receptor (37), we conducted 2 sets of additional in vivo experiments with short-term curcumin gavage and observed that the stimulatory effect of curcumin on hepatic Fgf21 and plasma Fgf21 levels occurred in the absence of dexamethasone administration. When the dosage of curcumin was 500 mg/kg body weight/d for 6 days, we observed elevated hepatic Fgf21 mRNA levels associated with elevated PPARa mRNA expression but without the increase of ambient circulating Fgf21 levels. When we reduced the dosage of curcumin to 100 mg/kg body weight/d for either 4 or 8 days, elevated circulating Fgf21 became appreciable, associated with increased hepatic Fgf21 mRNA and Fgf21 protein expression. Further investigations are needed to clarify whether multiple-day curcumin administration at a relatively higher dosage Figure 6 . Twelve-week curcumin intervention attenuates the effect of HFD feeding on hepatic gene expression. Liver tissues from the indicated groups of mice were collected for detecting the expression of Fgfr1 (A), bKlotho (B), Ppargc1a (C), as well as Acox, Pdk4, and Ehhadh (D). Expression levels of Pnpla2 (E), Lipe (F), and Mgll (G) in the indicated groups of mice. Expression levels of Ppargc1a (H) as well as Acox, Pdk4, and Ehhadh (I) in mice received with or without 6-day curcumin gavage. Values are means 6 SD (n = 5 for panels A-G; n = 6 for panels H and I). *P , 0.05 vs the corresponding control treatment. CUR, curcumin; V, control vehicle. doi: 10.1210/en.2016-1596 press.endocrine.org/journal/endoaffects Fgf21 hormone production or release or whether this is simply due to the variations among the animals. In our long-term intervention study, we prepared the diet containing 4 g curcumin per kg weight, as we had previously (26) ; this concentration of curcumin is much lower than the one used in a previous study by another team (25) . The fundamental role of PPAR family members, especially PPARa, in regulating hepatic Fgf21 expression has been demonstrated previously (1, 2, 8, 51, 53, 54) . It is well known that during starvation PPARa controls the utilization of fat as the alternative energy source, and it serves as the molecular target for the fibrate dyslipidemia drugs. Inagaki et al. (2) found that mouse hepatic Fgf21 expression is directly induced by PPARa in response to fasting, whereas Fgf21 mediates the pleiotropic effects of PPARa, including the stimulation of lipolysis in the white adipose tissue and ketogenesis in the liver. Badman et al. reported that hepatic Fgf21 expression and plasma Fgf21 levels were increased by fasting or ketogenic diet consumption but rapidly suppressed by refeeding (1) . Indeed, circulation Fgf21 levels can be elevated 5-to 10-fold after prolonged fasting (55) . Elevated hepatic Fgf21 expression Here we determined the stimulatory effect of curcumin treatment on Fgf21 transcription and suggest that it is unlikely that curcumin treatment increases Fgf21 mRNA stability because the decay of Fgf21 mRNA in the presence of actinomycin D was not affected by curcumin treatment. In addition to reproducing the observation that the PPARa agonist Wy-14643 stimulates Fgf21 expression in mouse hepatocytes, we observed in this study that curcumin-stimulated Fgf21 mRNA and Fgf21 protein expression can be blocked by the PPARa antagonist GW6471.
PPARa activation can be achieved by increasing its production, by reducing its phosphorylation at the S12 and S21 residues (38, 57, 58) , or, more powerfully, by ligand-induced activation. Although we observed the stimulation of curcumin on PPARa mRNA expression in vitro and in vivo with short-term curcumin gavage or longterm dietary intervention, we did not observe an appreciable stimulation on PPARa protein levels with curcumin treatment in mouse hepatocytes. Nevertheless, we observed that curcumin treatment reduced PPARa S12 levels in mouse hepatocytes.
The most profound effect on PPARa activation is mediated by the interaction with its ligands (54) . Our observations collectively suggest that curcumin cannot serve as a direct ligand for PPARa. In the HEK293 cell system, neither conditioned media from primary hepatocytes treated with 2 mM curcumin nor 10 mM curcumin on its own was able to stimulate GAL4-mPPARa, although we did observe a trend of activation with 10 mM curcumin on GAL4-RXR or GAL4-mVDR (Supplemental Fig. 5 ). In addition, we observed the stimulatory effect of curcumin in mouse primary hepatocytes on Fgf21 promoter PPRE1 and PPRE2 occupancy by PPARa with curcumin treatment for 4 hours but not for 0.5 hours, although profound stimulation was clearly demonstrated with the PPARa agonist Wy14643 for 0.5 hours. Therefore, we suggest that either curcumin treatment increases intracellular endogenous PPARa ligand levels or that curcumin itself can be metabolized within hepatocytes, generating a yet to be defined PPARa ligand, or that curcumin treatment affects the activity of PPARa by modifying its phosphorylation status. Intensive further investigations are required to test these potential underlying mechanisms.
Animals or human subjects with obesity or diabetes were paradoxically found to have elevated plasma Fgf21 levels, raising the suggestion that obesity is an Fgf21-resistant state (16) (17) (18) (19) (20) (21) . We reproduced the observation that HFD feeding reduced hepatic expression of Fgfr1 by Fisher et al. (16) and bKlotho by Rusie et al. (22) . We have also demonstrated that mouse primary hepatocytes receiving overnight Fgf21 treatment showed reduced Figure 8 . Illustration of the major findings of the study. Curcumin treatment activates PPARa. This can be achieved by attenuating its S12 phosphorylation, the generation of a yet to be identified ligand of PPARa, or the increase of the intracellular ligand levels. Activated PPARa upregulates Fgf21 mRNA transcription and Fgf21 protein production, involving the elevation of binding of PPARa to PPREs. It is likely that long-term curcumin intervention blocks HFD-induced Fgf21 resistance, involving the attenuation of the repression on FGFR1 and bKlotho expression by HFD feeding and the activation of the PPARa/Fgf21//PGC1a transcriptional axis (not detailed on the figure). press.endocrine.org/journal/endoexpression of these two genes and that curcumin intervention restored their expression in HFD-fed mice, along with the restoration of expression of genes that are downstream targets of the PPARa/PGC1a axis and genes that are involved in fatty acid b-oxidations. Finally, we demonstrated that the direct effects of Fgf21 treatment in mouse hepatocytes on Erk phosphorylation and the expression of Egr1 and cFos were blocked with HFD feeding and restored by curcumin intervention. These observations collectively suggest that curcumin intervention prevented the development of Fgf21 resistance in response to HFD consumption. Profound metabolic beneficial effects of dietary curcumin intervention have been demonstrated in animal models and in clinical trials (25) (26) (27) 30) . Many previous investigations have attributed the beneficial effects of dietary curcumin to its antioxidative stress and antiinflammation properties, secondary to the body weightlowering effect. We present here the in vitro and in vivo evidence for the role of curcumin in regulating Fgf21 production and function. Our in vitro study indicated that the dosage required for stimulating Fgf21 expression is much lower than that required for increasing HO1 and reducing nuclear factor kB (Supplemental Fig.  3 ). The bioavailability of curcumin and other dietary polyphenols is relatively low (59, 60) , raising the possibility that the observed in vivo anti-inflammation and antioxidative stress effects of curcumin intervention may be secondary to the regulation of Fgf21 expression and function.
A very recent study revealed that, in human subjects, insulin resistance is negatively associated with plasma levels of betaine, a modified amino acid found in many foods, including whole grains and sugar beet (61) . Dietary betaine supplementation was then demonstrated to increase Fgf21 levels, to improve glucose homeostasis, and to reduce hepatic steatosis in HFD-fed mice (61) . In contrast to this recent betaine study, we observed the attenuation effect of long-term curcumin intervention on hepatic Fgf21 production and its plasma level elevation. Figure 8 summarizes the major findings of this study. Our observations collectively suggest that curcumin activates PPARa indirectly. This can be achieved by blocking its S12 phosphorylation or by facilitating the generation of intracellular PPARa ligands. These mechanisms, however, are not mutually exclusive. Activated PPARa upregulates Fgf21 transcription and protein production via binding to the 2 evolutionarily conserved PPREs. Importantly, long-term curcumin intervention blocks HFD-induced Fgf21 resistance, involving the attenuation of the reduction of FGFR1 and bKlotho expression by HFD feeding and the activation of the PPARa/Fgf21//PGC1a axis. This study has expanded the mechanistic exploration of the beneficial metabolic effects of curcumin from its anti-inflammation and antioxidative stress roles to the regulation of Fgf21 production and function. It remains to be assessed whether these effects apply to other dietary polyphenols.
